You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and clinical assessment of a robust, 3D printed titanium, myoelectric powered prosthetic digit system

    SBC: POINT DESIGNS, LLC            Topic: 106

    ABSTRACT Approximately 600,000 people live with partial hand amputations in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for patie ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. The first clinical use of the BiVACOR Total Artificial Heart

    SBC: BIVACOR INC            Topic: NHLBI

    SUMMARY/ABSTRACT Heart Failure (HF) is a devastating epidemic affecting more than 23 million patients worldwide; in the U.S. alone, 1,000,000 new cases are reported each year. While heart transplantation provides the best treatment option for many patients, less than 6,000 procedures take place globally each year. Consequently, it is estimated that 50,000 – 100,000 patients could immediately ben ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NIBIB

    Project Summary/Abstract The United States is experiencing an epidemic of unprecedented scope with heroin use resurging and a troubling pervasive increase in abuse of prescription opioids such as fentanyl, fentanyl derivatives, methadone, oxycodone and hydrocodone. More than 6 out of 10 drug overdoses are now opioid-related, resulting in ~90 deaths/day and a more than $75B/year economic impact. Ad ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

    SBC: Marker Therapeutics, Inc.            Topic: NCI

    ABSTRACT This Phase II application will advance MT-401, a novel multi-tumor associated antigen (mTAA)-specific T cell product for the treatment of acute myeloid leukemia (AML) and other cancers. In the USA, ~3,500 AML patients receive hematopoietic stem cell therapy (HSCT) every year, but overall survival remains lt30%, with an estimated median survival of lt1 year. Although AML is sensitive to im ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza

    SBC: TFF PHARMACEUTICALS, INC.            Topic: NIAID

    PROJECT SUMMARY TFF Pharmaceuticals (TFFP) is developing a shelf-stable thin-film freeze (TFF) dry powder universal flu vaccine. Commercialization of this product would provide the first vaccine that is at least 75% effective against symptomatic influenza virus infection, with the added benefit of easy delivery and storage at room temperature to facilitate broad, cost-effective distribution. With ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots

    SBC: Microgen LLC            Topic: NIDCD

    Project Summary Sensorineural hearing loss (SNHL), a condition where the inner ear cannot convert sound into nerve impulses to the brain, is the most common congenital disease. The leading cause of non-genetic SNHL is congenital cytomegalovirus (cCMV) infection, and the economic burden of SNHL and its detrimental effect on language development in the US is estimated at nearly $4 billion annually. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Comparative testing of tatCN19o for neuroprotection in rodent tMCAo

    SBC: NEUREXIS THERAPEUTICS, INC.            Topic: NINDS

    Project Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Depleting autoantibodies for the treatment of autoimmunity

    SBC: ASTERO ERADO INC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The overall goal of this project is to develop a novel therapeutic for the treatment of primary (idiopathic) membranous nephropathy (MN). MN is a leading cause of nephrotic syndrome in adults and has a variable clinical course. About one third of patients enter spontaneous remission, whereas the remainder have persistent proteinuria that can lead to end stage renal disease ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Live spike sorting for multichannel and high-channel recordings

    SBC: POPNEURON LLC            Topic: 106

    Project Summary: The goal of this project is to create two prototypes of a novel live spike sorting system which can be used by investigators to spike sort streams of neural data recorded by multi-channel, high channel and ultra-high channel probes. In most in-vivo extracellular recording conditions, an electrode can pick up neural spikes from several nearby neurons resulting in so-called “multi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government